Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CARsgen Therapeutics Holdings Ltd. ( (HK:2171) ) just unveiled an update.
CARsgen Therapeutics Holdings Ltd. announced the presentation of research results from an investigator-initiated trial of CT071, a CAR T-cell therapy candidate targeting GPRC5D for newly diagnosed multiple myeloma, at the 30th Annual Congress of the European Hematology Association. The ongoing trials in China aim to evaluate the safety and efficacy of CT071 for both relapsed/refractory multiple myeloma and newly diagnosed cases, potentially impacting the company’s standing in the biopharmaceutical industry by addressing significant clinical needs.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$8.96 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
More about CARsgen Therapeutics Holdings Ltd.
CARsgen Therapeutics Holdings Ltd. is a biopharmaceutical company specializing in the development of innovative CAR T-cell therapies aimed at addressing unmet clinical needs in hematologic malignancies, solid tumors, and autoimmune diseases. The company boasts comprehensive capabilities in CAR T-cell research and development, including target discovery, preclinical research, clinical development, and commercial-scale production. CARsgen is committed to enhancing the safety and efficacy of CAR T-cell therapies and reducing treatment costs, with a mission to become a global leader in providing innovative and differentiated cell therapies.
Average Trading Volume: 3,313,292
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.41B
See more insights into 2171 stock on TipRanks’ Stock Analysis page.